European journal of clinical investigation
-
Eur. J. Clin. Invest. · Dec 2022
Multicenter StudyEffect of PCSK9 inhibitors on cholesterol remnants and lipid residual risk: the LIPID-REAL Registry.
Monoclonal antibodies that inhibit the proprotein convertase subtilisin/kexin type 9 (PCSK9) reduce low-density lipoprotein cholesterol (LDLc) by 55%, regardless of baseline treatments. Nonetheless, the effect of other lipid parameters, such as cholesterol remnants or, the so-called lipid residual risk, is unknown. ⋯ This multicenter and retrospective registry of real-world patients treated with PCSK9 inhibitors demonstrates a positive effect on cholesterol remnants and lipid residual risk beyond LDLc reductions.